Document Detail


Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol.
MedLine Citation:
PMID:  21921959     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate the optical and anatomical effects of oral propranolol treatment for infantile periocular capillary haemangioma.
METHODS: All children diagnosed with infantile capillary haemangioma in 2008-2010 at a tertiary paediatric medical centre underwent comprehensive evaluation, including imaging, by a multidisciplinary team followed by oral propranolol treatment. Clinical follow-up was performed regularly until the lesions disappeared. Main outcome measures included changes in anatomical extraocular extension, refractive sphere and cylindrical power, and spherical equivalent in the involved eye before and after treatment and between the two eyes.
RESULTS: A total of 30 patients (8 male; mean age at diagnosis, 1.6±2.8 months) participated. The lesions affected the left eye in 53.3% and were located preseptally in 83.3%. Four patients (13.3%) received steroids before propranolol. A treatment dosage of 2 mg/kg per day was started at mean age 5.0±4.5 months, 3.3±4.3 months from disease onset. Side effects occurred in 11 patients and warranted a dose reduction (to 1 mg/kg per day) in 3 and treatment termination in 1. Findings were significant for mean reduction in involved extraocular area (P<0.0001), post-treatment reduction in mean cylindrical power in involved eyes (P=0.02), pre- and post-treatment differences in mean cylindrical power between involved and uninvolved eyes (P=0.02 and P=0.01, respectively), and post-treatment change in absolute values of mean spherical power between involved and uninvolved eyes (P=0.025).
CONCLUSIONS: Early diagnosis of infantile periocular capillary haemangioma and prompt treatment with propranolol lead to a significant reduction in the involved ocular area, in astigmatism, and prevent ocular/facial disfiguration/deformation, without rebound. Propranolol is recommended as the preferred treatment compared with other accepted therapies.
Authors:
M Snir; U Reich; R Siegel; A Zvulunov; R Friling; N Goldenberg-Cohen; Y Ron; D Ben-Amitay
Related Documents :
21380609 - Nocturnal moaning and groaning-catathrenia or nocturnal vocalizations.
21366389 - Fragmented sleep: an unrevealed problem in peritoneal dialysis patients.
21263879 - Obstructive sleep apnea: a clinical review.
21243439 - Epworth sleepiness scale may be an indicator for blood pressure profile and prevalence ...
25072649 - Therapeutic outcomes of retinal hemangioblastomas.
18848319 - Longitudinal cohort study of patients with birdshot chorioretinopathy. v. quality of li...
19301709 - Apoc impact assessment studies: baseline ophthalmological findings in morogoro, tanzania.
23492459 - Discovery of some 400 million year-old sensory structures in the compound eyes of trilo...
11290379 - 8-oh-dpat and mk-801 affect epileptic activity independently of vigilance.
Publication Detail:
Type:  Journal Article     Date:  2011-09-16
Journal Detail:
Title:  Eye (London, England)     Volume:  25     ISSN:  1476-5454     ISO Abbreviation:  Eye (Lond)     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-13     Completed Date:  2012-02-06     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  8703986     Medline TA:  Eye (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  1627-34     Citation Subset:  IM    
Affiliation:
Unit of Pediatric Ophthalmology, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. msnir@clalit.org.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Eyelid Neoplasms / drug therapy*,  pathology,  physiopathology
Female
Hemangioma, Capillary / drug therapy*,  pathology,  physiopathology
Humans
Infant
Male
Neoplastic Syndromes, Hereditary / drug therapy*,  pathology,  physiopathology
Orbital Neoplasms / drug therapy*,  pathology,  physiopathology
Propranolol / therapeutic use*
Refraction, Ocular / physiology*
Retrospective Studies
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 525-66-6/Propranolol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective st...
Next Document:  Photocarcinogenesis study of glycolic acid and salicylic acid (CAS Nos. 79-14-1 and 69-72-7) in SKH-...